Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 963-971

  De Kreuk, A M ^a   Ossenkoppele, G J ^a   Meijer, C J L M ^a   Huijgens, P C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABMT; Coiffier index; High dose chemotherapy; NHL; Prognostic factors; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER STAGING; DEATH; DRUG FATALITY; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; SURVIVAL; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030057422     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. The International Non-Hodgkin's Lymphoma Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
2. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211-219.
3. Armitage JO, Weisenburger DD, Hutchins M et al. Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160-164.
4. Vose JM, Armitage JO. Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1993; 7: 577-590.
5. Fisher RI, Gaynor ER, Dahlberg S et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5 (Suppl. 2): 91-95.
6. Cooper IA, Wolf MM, Robertson TI et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994; 12: 769-778.
7. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
8. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-594.
9. Bosly A, Coiffier B, Gisselbrecht C et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615-1623.
10. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
11. Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. New Engl J Med 1987; 316: 1499-1505.
12. Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 1992; 10: 942-947.
13. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.
14. Colombat P, Donadio D, Fouillard L et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157-162.
15. Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085-1091.
16. Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358-1365.
17. Conde E, Sierra J, Iriondo A et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Transplant 1994, 14: 279-286.
18. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11: 931-936.
19. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
20. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
21. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977; 61: 1023-1027.
22. Cowan RA, Jones M, Harris M et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer 1989; 59: 276-282.
23. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has 'high-risk' disease? Blood 1994; 83: 1165-1173.
24. Lopez Guillermo A, Montserrat E, Bosch F et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-1348.
25. Child JA, Barnard DL, Cartwright SC et al. A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MIX-CHOP) in poor prognosis non-Hodgkin's lymphoma (NHL). Cancer Chemother Pharmacol 1983; 11: 153-158.
26. Gomez GA, Barcos M, Han T, Henderson ES. Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology. Cancer 1987; 60: 18-24.
27. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
28. Ashwood-Smith MJ. Preservation of mouse bone marrow at 79°C with dimethyl sulphoxide. Nature 1961; 190: 1204-1205.
29. Lovelock JE, Bishop MWH. Prevention of freezing damage to living cells by dimethyl sulphoxide. Nature 1959; 183: 1394-1395.
30. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
31. Colombat Ph, Biron P, Laporte JP. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. (letter) Eur J Cancer 1990; 26: 858.
32. SPSS. SPSS Statistical Software Release 6.0. SPSS: Chicago, 1993.
33. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
34. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
35. Philip T, Hartmann O, Biron P et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118-1124.
36. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
37. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
38. Verdonck LF, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New Engl J Med 1995; 332: 1045-1051.
39. Nimer SD, Zelenetz A, Portlock C. Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma (correspondence). New Engl J Med 1995; 333: 728-729.
40. Fielding AK, Pearce RM, Goldstone AH. Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma (correspondence). New Engl J Med 1995; 333: 729.
41. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
42. Haq R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994; 12: 1074-1084.
43. Lazarus HM, Crilley P, Ciobanu N et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992; 10: 1682-1689.